Search for authorsSearch for similar articles
7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Computer-aided pattern scoring (C@PS): a novel cheminformatic workflow to predict ligands with rare modes-of-action

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The identification, establishment, and exploration of potential pharmacological drug targets are major steps of the drug development pipeline. Target validation requires diverse chemical tools that come with a spectrum of functionality, e.g., inhibitors, activators, and other modulators. Particularly tools with rare modes-of-action allow for a proper kinetic and functional characterization of the targets-of-interest ( e.g., channels, enzymes, receptors, or transporters). Despite, functional innovation is a prime criterion for patentability and commercial exploitation, which may lead to therapeutic benefit. Unfortunately, data on new, and thus, undruggable or barely druggable targets are scarce and mostly available for mainstream modes-of-action only ( e.g., inhibition). Here we present a novel cheminformatic workflow—computer-aided pattern scoring (C@PS)—which was specifically designed to project its prediction capabilities into an uncharted domain of applicability.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13321-024-00901-5.

          Scientific contribution

          The presented workflow tackles, for the first time, the challenge of data scarcity particularly focusing rare modes-of-action. In addition, the workflow and associated dataset provide new standards in the definition and application of criteria to rationalize drug candidate selection addressing important gaps in cheminformatics as well as computational and medicinal chemistry.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13321-024-00901-5.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Advances in covalent drug discovery

          Covalent drugs have been used to treat diseases for more than a century, but tools that facilitate the rational design of covalent drugs have emerged more recently. The purposeful addition of reactive functional groups to existing ligands can enable potent and selective inhibition of target proteins, as demonstrated by the covalent epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK) inhibitors used to treat various cancers. Moreover, the identification of covalent ligands through ‘electrophile-first’ approaches has also led to the discovery of covalent drugs, such as covalent inhibitors for KRAS(G12C) and SARS-CoV-2 main protease. In particular, the discovery of KRAS(G12C) inhibitors validates the use of covalent screening technologies, which have become more powerful and widespread over the past decade. Chemoproteomics platforms have emerged to complement covalent ligand screening and assist in ligand discovery, selectivity profiling and target identification. This Review showcases covalent drug discovery milestones with emphasis on the lessons learned from these programmes and how an evolving toolbox of covalent drug discovery techniques facilitates success in this field. The rational discovery of covalent drugs depends on an expanding toolset of techniques. Here, Daniel Nomura and colleagues highlight covalent drugs that have achieved success over the past decade and discuss the tools and strategies that facilitate their discovery, describing two complementary approaches, namely, ligand-first and electrophile-first strategies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice.

            In Alzheimer disease (AD), the intracerebral accumulation of amyloid-β (Aβ) peptides is a critical yet poorly understood process. Aβ clearance via the blood-brain barrier is reduced by approximately 30% in AD patients, but the underlying mechanisms remain elusive. ABC transporters have been implicated in the regulation of Aβ levels in the brain. Using a mouse model of AD in which the animals were further genetically modified to lack specific ABC transporters, here we have shown that the transporter ABCC1 has an important role in cerebral Aβ clearance and accumulation. Deficiency of ABCC1 substantially increased cerebral Aβ levels without altering the expression of most enzymes that would favor the production of Aβ from the Aβ precursor protein. In contrast, activation of ABCC1 using thiethylperazine (a drug approved by the FDA to relieve nausea and vomiting) markedly reduced Aβ load in a mouse model of AD expressing ABCC1 but not in such mice lacking ABCC1. Thus, by altering the temporal aggregation profile of Aβ, pharmacological activation of ABC transporters could impede the neurodegenerative cascade that culminates in the dementia of AD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Proteolysis-targeting chimeras (PROTACs) in cancer therapy

              Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system. PROTAC has emerged as a promising approach for targeted therapy in various diseases, particularly in cancers. In this review, we introduce the principle and development of PROTAC technology, as well as the advantages of PROTACs over traditional anti-cancer therapies. Moreover, we summarize the application of PROTACs in targeting critical oncoproteins, provide the guidelines for the molecular design of PROTACs and discuss the challenges in the targeted degradation by PROTACs.
                Bookmark

                Author and article information

                Contributors
                vnamasiv@uni-bonn.de , vigneshwaran.namasivayam@uksh.de
                Journal
                J Cheminform
                J Cheminform
                Journal of Cheminformatics
                Springer International Publishing (Cham )
                1758-2946
                23 September 2024
                23 September 2024
                2024
                : 16
                : 108
                Affiliations
                [1 ]GRID grid.5510.1, ISNI 0000 0004 1936 8921, Department of Pathology, , University of Oslo and Oslo University Hospital, ; Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway
                [2 ]Lübeck Institute of Experimental Dermatology, Medical Systems Biology Division, Medicinal Chemistry and Systems Polypharmacology, University of Lübeck and University Medical Center Schleswig-Holstein, ( https://ror.org/00t3r8h32) Ratzeburger Allee 160, 23538 Lübeck, Germany
                [3 ]Department of Biopharmacy, Medical University of Lublin, ( https://ror.org/016f61126) Chodzki 4a, 20-093 Lublin, Poland
                [4 ]Pharmaceutical Institute, Department of Pharmaceutical and Cellbiological Chemistry, University of Bonn, ( https://ror.org/041nas322) An der Immenburg 4, 53121 Bonn, Germany
                Article
                901
                10.1186/s13321-024-00901-5
                11421111
                39313842
                040cfcb1-d8ee-4637-9c71-b7965f14eaa5
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 16 May 2024
                : 5 September 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft;
                Award ID: #446812474
                Award ID: #537276156
                Award ID: #504079349 (PANABC)
                Award Recipient :
                Funded by: Rheinische Friedrich-Wilhelms-Universität Bonn (1040)
                Categories
                Methodology
                Custom metadata
                © Springer Nature Switzerland AG 2024

                Chemoinformatics
                Chemoinformatics

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content118

                Most referenced authors187